Last updated: April 26, 2026
Disulfiram is a legacy thiuram-disulfide drug used in alcohol-use disorder (and other indications in specialty settings). Supply is split across API makers and finished-dose manufacturers (FDF). The supplier set varies by target market, regulatory status, and whether buyers require DMF/ASMF coverage and GMP certification.
Who supplies disulfiram API?
Disulfiram API is supplied by chemical and generic API manufacturers that operate under GMP and provide dossier support (ASMF/DMF or equivalent) for regulatory submissions.
Typical API procurement channels for disulfiram:
- Generic API manufacturers offering DMF/ASMF packages for global submissions
- Intermediates suppliers that support API contract manufacture (where buyers outsource synthesis and purification)
- Regional wholesalers and brokers that aggregate multiple API sources (useful for availability and lead-time control)
Which finished-dose suppliers sell disulfiram tablets?
Finished-dose (FDF) supply is dominated by generic manufacturers across the US and EU, with market-specific label holders and distributors. Buyers normally source through:
- ANDA/Biologic License substitute channels (US generics with approved applications)
- National marketing authorization holders (EU member-state markets)
- Authorized distributors for continuity of supply
What supplier qualification artifacts buyers should expect
Procurement for disulfiram API and FDF generally hinges on documentation that regulators and QA teams request during supplier onboarding.
For API, buyers typically require:
- GMP certificate for the manufacturing site
- CoA (certificate of analysis) aligned to specification
- DMF/ASMF access or cross-reference letter
- Impurity profile and limits (including key related substances)
- Stability data for shelf-life assignment
For finished dose, buyers typically require:
- GMP certificate for tablet manufacturing site(s)
- Batch records traceability and QA release testing
- Specification for tablet potency and impurity thresholds
- Country of origin and serialization (where applicable)
Market-facing supplier map (API vs FDF)
Below is the practical structure of how disulfiram is typically sourced for commercial supply, by product form.
API sourcing structure
- Primary API manufacturers: sell disulfiram API directly under commercial agreement
- Contract manufacturing: provide disulfiram API under toll or CMO arrangements for buyers that specify process and specs
- Trading distributors: provide quick access but may add lead time for CoA batching and regulatory document transfers
Finished-dose sourcing structure
- Generic label holders: control regulatory dossier and batch release for each market
- Contract packagers: package tablets from bulk API or from bulk tablets into market-specific pack formats
- Regional distributors: manage cold/ambient logistics, channel fill targets, and tender compliance
How buyers usually narrow supplier selection for disulfiram
Commercial procurement for a legacy, small-molecule drug tends to reduce to these filters:
- Regulatory readiness: DMF/ASMF coverage aligned to target country submissions
- Supply continuity: ability to meet rolling demand and reduce stock-out risk
- Quality control alignment: impurity and polymorph control, and method validation package acceptance
- Pricing and contracts: multi-year framework pricing versus spot availability
Key takeaways
- Disulfiram supply is split between API manufacturers and finished-dose generic suppliers, with the supplier roster changing by market.
- Procurement success depends on GMP documentation, DMF/ASMF dossier access, impurity/spec compliance, and batch traceability.
- Buyers typically reduce the supplier set using regulatory readiness and supply continuity, not just unit price.
FAQs
-
Is disulfiram generally available as an API from multiple suppliers?
Yes, disulfiram API is supplied by multiple global generic API manufacturers, though the availability of dossier documents and GMP coverage varies by site and country.
-
Do finished-dose brands matter more than API sources for regulatory approvals?
For FDF markets, regulatory clearance and batch release are label-holder specific, so both API assurance and the tablet manufacturer’s GMP release system matter.
-
What documentation is most important when onboarding a disulfiram API supplier?
GMP certificate, CoA-to-spec alignment, DMF/ASMF (or equivalent dossier support), impurity profile, and stability data.
-
Can disulfiram be sourced via contract manufacturing?
Yes. Buyers commonly use tolling or CMO arrangements to ensure process control and specification compliance across batches.
-
What tends to cause supply disruptions for legacy drugs like disulfiram?
Capacity shifts at older chemical sites, dossier/quality changes at manufacturing sites, and commercial contract re-pricing that leads to temporary allocation.
References
[1] FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA European Public Assessment Reports (EPAR) and related information. European Medicines Agency. https://www.ema.europa.eu/en/medicines
[3] GMP certificates and manufacturer listings via WHO prequalification and national regulator databases (varies by jurisdiction). World Health Organization. https://extranet.who.int/prequal/
